Sunesis issues 404,040 shares to Bristol-Myers

By Lisa Kerner

Erie, Pa., Feb. 15 - Sunesis Pharmaceuticals, Inc. issued 404,040 shares of common stock to Bristol-Myers Squibb Co., according to a company news release.

The shares were issued as consideration for a milestone payment due as the result of a license agreement dated April 27, 2005 between the Sunesis and Bristol-Myers.

The stock is not registered and Bristol-Myers is intending to acquire the securities for investment only and not for distribution.

Sunesis is a clinical stage biopharmaceutical company focused on small molecule therapeutics for oncology, inflammatory diseases and other unmet medical needs. The company is located in South San Francisco.

Sunesis shares (Nasdaq: SNSS) ended Wednesday up 17 cents, or 3.40%, at $5.17.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.